Roche Holding agreed to collaborate with Phoenix Molecular Designs to develop an assay that will detect activation of RPS6KA3 in patients with triple-negative breast cancer. Phoenix intends to use the diagnostic in a Phase I/Ib trial of its drug candidate PMD026 this year.
Roche signs triple-negative breast cancer biomarker deal with Phoenix
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.